Format

Send to

Choose Destination
See comment in PubMed Commons below
J Biol Chem. 2013 May 10;288(19):13655-68. doi: 10.1074/jbc.M113.455485. Epub 2013 Mar 22.

Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR.

Author information

1
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA.

Abstract

BACKGROUND:

Ketoconazole binds to and antagonizes pregnane X receptor (PXR) activation.

RESULTS:

Yeast high throughput screens of PXR mutants define a unique region for ketoconazole binding.

CONCLUSION:

Ketoconazole genetically interacts with specific PXR surface residues.

SIGNIFICANCE:

A yeast-based genetic method to discover novel nuclear receptor interactions with ligands that associate with surface binding sites is suggested. The pregnane X receptor (PXR) is a master regulator of xenobiotic metabolism, and its activity is critical toward understanding the pathophysiology of several diseases, including inflammation, cancer, and steatosis. Previous studies have demonstrated that ketoconazole binds to ligand-activated PXR and antagonizes receptor control of gene expression. Structure-function as well as computational docking analysis suggested a putative binding region containing critical charge clamp residues Gln-272, and Phe-264 on the AF-2 surface of PXR. To define the antagonist binding surface(s) of PXR, we developed a novel assay to identify key amino acid residues on PXR based on a yeast two-hybrid screen that examined mutant forms of PXR. This screen identified multiple "gain-of-function" mutants that were "resistant" to the PXR antagonist effects of ketoconazole. We then compared our screen results identifying key PXR residues to those predicted by computational methods. Of 15 potential or putative binding residues based on docking, we identified three residues in the yeast screen that were then systematically verified to functionally interact with ketoconazole using mammalian assays. Among the residues confirmed by our study was Ser-208, which is on the opposite side of the protein from the AF-2 region critical for receptor regulation. The identification of new locations for antagonist binding on the surface or buried in PXR indicates novel aspects to the mechanism of receptor antagonism. These results significantly expand our understanding of antagonist binding sites on the surface of PXR and suggest new avenues to regulate this receptor for clinical applications.

KEYWORDS:

Antagonist; Drug Development; Drug Metabolism; Ketoconazole; Mutagenesis; Nuclear Receptors; Pregnane X Receptor; Protein Drug Interactions; Proteomics; Yeast Two-hybrid

PMID:
23525103
PMCID:
PMC3650402
DOI:
10.1074/jbc.M113.455485
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center